Готові списки джерел за темами / Radiotherapy

Зміст

Статті в журналах
Дисертації
Книги
Частини книг
Тези доповідей конференцій
Звіти організацій

Добірка наукової літератури з теми "Radiotherapy"

Автор: Grafiati

Опубліковано: 4 червня 2021

Оновлено: 26 жовтня 2024

Оформте джерело за APA, MLA, Chicago, Harvard та іншими стилями

Оберіть тип джерела:

Ознайомтеся зі списками актуальних статей, книг, дисертацій, тез та інших наукових джерел на тему "Radiotherapy".

Біля кожної праці в переліку літератури доступна кнопка «Додати до бібліографії». Скористайтеся нею – і ми автоматично оформимо бібліографічне посилання на обрану працю в потрібному вам стилі цитування: APA, MLA, «Гарвард», «Чикаго», «Ванкувер» тощо.

Також ви можете завантажити повний текст наукової публікації у форматі «.pdf» та прочитати онлайн анотацію до роботи, якщо відповідні параметри наявні в метаданих.

Статті в журналах з теми "Radiotherapy"

Park, Jung-ho. "Acuros XB for Dose Calculations in External Beam Photon Radiotherapy-Mini Review." Trends Journal of Sciences Research 1, no. 1 (December 30, 2014): 26–27. http://dx.doi.org/10.31586/radiotherapy.0101.04.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Du, Yan, and Yong Zeng. "Analysis of postoperative radiotherapy for non-metastatic head and neck adenoid cystic carcinoma based on SEER data." Journal of International Medical Research 50, no. 8 (August 2022): 030006052211151. http://dx.doi.org/10.1177/03000605221115151.

Повний текст джерела

Анотація:

Objective The postoperative role of adjuvant radiotherapy in non-metastatic head and neck adenoid cystic carcinoma (ACC) remains controversial. We analyzed adjuvant radiotherapy’s effect on surgical patient survival. Methods Patients diagnosed with ACC from 2004 to 2015 in the Surveillance, Epidemiology, and End Results database were analyzed. The overall survival (OS) and disease-specific survival (DSS) of patients after adjuvant radiotherapy were assessed using the Kaplan–Meier and multivariate Cox methods. Propensity score matching (PSM) was performed to adjust confounders between patients with or without adjuvant radiotherapy; a forest plot was generated by subgroup analysis. Results The study included 742 patients. In the PSM cohort, adjuvant radiotherapy did not improve OS or DSS. Radiotherapy was not a protective factor for OS or DSS in the univariate and multivariate Cox proportional hazard models. In the subgroup analysis, postoperative radiotherapy improved the OS of female and N1-stage patients and those with oropharyngeal tumors or over 79 years and the DSS of N1-stage patients. Conclusions Postoperative radiotherapy showed different benefits in ACC patients, and postoperative radiotherapy recommendations should be individualized. Female and N1-stage ACC patients and those with oropharyngeal tumors or patients over 79 years without distant metastases postoperatively could benefit from adjuvant radiotherapy.

Стилі APA, Harvard, Vancouver, ISO та ін.

Chandra, Ade, Sukri Rahman, Al Hafiz, Eva Decroli, and Hafni Bachtiar. "Pengaruh Radioterapi Terhadap Kadar TSH dan T4 pada Pasien Tumor Ganas Kepala dan Leher." Oto Rhino Laryngologica Indonesiana 48, no. 2 (January 30, 2019): 159. http://dx.doi.org/10.32637/orli.v48i2.238.

Повний текст джерела

Анотація:

Latar belakang: Tumor ganas kepala dan leher adalah tumor ganas yang berasal dari epitel traktus aerodigestif atas. Radioterapi adalah salah satu modalitas talaksana pada tumor ganas kepala dan leher. Kelenjar tiroid akan terpapar radioterapi selanjutnya merangsang terjadinya kelainan pada kelenjar tiroid. Hipotiroid merupakan efek samping yang paling umum terjadi akibat radioterapi. Diagnosis hipotiroid ditegakkan melalui pemeriksaan laboratorium yaitu didapatkan peningkatan TSH dan penurunan T4. Tujuan: Mengetahui pengaruh radioterapi terhadap kadar TSH dan T4 pasien tumor ganas kepala dan leher di RSUP Dr. M. Djamil, Padang. Metode: Analitik cross sectional dengan desian pre and post test only pada 10 responden tumor ganas kepala dan leher. Sampel berupa darah vena yang dihitung kadar TSH dan T4 menggunakan alat Vidas 3. Data dianalisis dengan uji t berpasangan. Hasil analisis statistik dinyatakan bermakna bila didapatkan hasil p<0,05. Hasil: Nilai rerata kadar TSH sebelum dan setelah radioterapi didapatkan 0,57 ± 0,512 µIU/ml. Nilai rerata kadar T4 sebelum dan setelah radioterapi didapatkan 0,721 ± 0,508 µg/dL. Uji t bepasangan didapatkan peningkatan rerata kadar TSH setelah radioterapi dengan p = 0,004 yang menunjukkan peningkatan bermakna rerata kadar TSH setelah radioterapi dan didapatkan penurunan rerata kadar T4 setelah radioterapi dengan p = 0,001 yang menunjukkan penurunan bermakna rerata kadar T4 setelah radioterapi. Kesimpulan: Terdapat peningkatan bermakna rerata kadar TSH serta penurunan rerata kadar T4 sebelum dan setelah radioterapi pada pasien tumor ganas kepala dan leher walau belum melewati nilai normal.ABSTARCTBackground: Head and neck cancers are malignancies that originate from upper aerodigestive tract epithelium. Radiotherapy is one of the modalities treatments for head and neck cancer. Thyroid glands which exposed by radiotherapy, furthermore can induce abnormalities. Hypothyroid is a most common abnormality that occur after radiotherapy. Diagnosis hypothyroidism can be established through laboratory examination that is obtained an increased levels of TSH and decreased levels of T4. Purpose: To determine effect radiotherapy on levels of TSH and T4 in patients with head and neck cancer in Dr. M. Djamil Hospital, Padang. Methods: Cross sectional analytic study with pre and post test only on 10 respondents with head and neck cancer. Samples taken from venous blood then TSH and T4 were counted with Vidas 3. Data was analyzed with paired t-test. The statistical result was significant with p<0,05. Result: Mean value of TSH before and after radiotherapy is 0,57 ± 0,512 µUI/ml. Mean value of T4 before and after radiotherapy is 0,721 ± 0,508 µg/dL. From paired t-test resulted an increase of TSH mean value after radiotheraphy with p = 0,004 which implies a significant enhancement of TSH mean value after radiotheraphy and decreasing T4 mean value after radiotheraphy with p = 0,001 which implies a significant deflation of T4 mean value after radiotheraphy. Conclusions: There was significant enhancement of TSH mean and significant deflation of T4 mean value before and after radiotherapy on patients with head and neck cancer even still within normal value. Keywords: Radiotheraphy, TSH, T4, head and neck cancer.

Стилі APA, Harvard, Vancouver, ISO та ін.

Dona Lemus, Olga Maria, Minsong Cao, Bin Cai, Michael Cummings, and Dandan Zheng. "Adaptive Radiotherapy: Next-Generation Radiotherapy." Cancers 16, no. 6 (March 19, 2024): 1206. http://dx.doi.org/10.3390/cancers16061206.

Повний текст джерела

Анотація:

Radiotherapy, a crucial technique in cancer therapy, has traditionally relied on the premise of largely unchanging patient anatomy during the treatment course and encompassing uncertainties by target margins. This review introduces adaptive radiotherapy (ART), a notable innovation that addresses anatomy changes and optimizes the therapeutic ratio. ART utilizes advanced imaging techniques such as CT, MRI, and PET to modify the treatment plan based on observed anatomical changes and even biological changes during the course of treatment. The narrative review provides a comprehensive guide on ART for healthcare professionals and trainees in radiation oncology and anyone else interested in the topic. The incorporation of artificial intelligence in ART has played a crucial role in improving effectiveness, particularly in contour segmentation, treatment planning, and quality assurance. This has expedited the process to render online ART feasible, lowered the burden for radiation oncology practitioners, and enhanced the precision of dynamically personalized treatment. Current technical and clinical progress on ART is discussed in this review, highlighting the ongoing development of imaging technologies and AI and emphasizing their contribution to enhancing the applicability and effectiveness of ART.

Стилі APA, Harvard, Vancouver, ISO та ін.

Shumway, Dean Alden, Kent A. Griffith, Michael S. Sabel, Rochelle Jones, Sarah T. Hawley, Jacqueline Sara Jeruss, and Reshma Jagsi. "What drives overtreatment? Surgeon and radiation oncologist views on omission of adjuvant radiotherapy for elderly women with early stage breast cancer." Journal of Clinical Oncology 35, no. 15_suppl (May 20, 2017): 562. http://dx.doi.org/10.1200/jco.2017.35.15_suppl.562.

Повний текст джерела

Анотація:

562 Background: Although trials have shown no survival advantage and only a modest improvement in local control from adjuvant radiotherapy after lumpectomy in older women with stage I, ER+ breast cancer, radiotherapy is commonly administered, raising concerns about overtreatment. Therefore, we sought to evaluate physician attitudes, knowledge, communication, and recommendations in this scenario. Methods: We mailed a survey to a national sample of 713 radiation oncologists and 879 surgeons between June to October 2015. Of these, 913 responded (57%). We assessed physicians’ attitudes, knowledge of pertinent risk information, and responses to clinical scenarios. Results: In patients age > = 70 with stage I, ER+ breast cancer treated with lumpectomy and endocrine therapy, omission of radiotherapy was felt to be unreasonable by 40% of surgeons and 20% of radiation oncologists (p < 0.001). Many surgeons (29%) and radiation oncologists (10%) erroneously associated radiotherapy in older women with improvement in survival. Similarly, 32% of surgeons and 19% of radiation oncologists tended to substantially overestimate the risk of locoregional recurrence in older women with omission of RT. In a scenario with an 81-year-old with multiple comorbidities, 31% of surgeons and 35% of radiation oncologists would still recommend radiotherapy. On multivariable analysis, erroneous attribution of a survival benefit to radiotherapy (OR 6.2; 95% CI 3.9-9.8) and overestimation of remaining life expectancy (OR 6.5; CI 4.2-9.9) were strongly associated with the opinion that radiotherapy omission is unreasonable. Conclusions: Many radiation oncologists and surgeons continue to consider omission of radiotherapy as substandard therapy. A sizeable proportion of surgeons overestimate radiotherapy’s benefits and consider omission of radiotherapy to be an unreasonable departure from the standard of care, suggesting that surgeon involvement in decisions about radiotherapy omission may be a key factor in reducing overuse of aggressive care in this setting.

Стилі APA, Harvard, Vancouver, ISO та ін.

Pandey, Dr Vivek Kumar. "Prospective Study to Compare Outcomes Following Hypofractionated Radiotherapy versus Conventional Radiotherapy in Carcinoma Breast." Journal of Medical Science And clinical Research 11, no. 07 (July 30, 2023): 15–26. http://dx.doi.org/10.18535/jmscr/v11i7.04.

Повний текст джерела

Анотація:

Background: Breast cancer is now the most common cancer worldwide (GLOBOCAN, 2020). It is the most common cancer among women in developed countries. The age standardized incidence rate of breast cancer in India is 25.8% per 100,000 women (GLOBOCAN, 2020). By 2020, breast cancer overtook cervical cancer as the most common type of cancer among all women in India. Breast irradiation has been shown to reduce the risk of local recurrence after breast-conserving surgery from about 30% to <10% at 10 years. Aims & Objectives: Randomize Breast carcinoma into two arms - Arm A :- 39GY in 13 fractions over 2.3 weeks & Arm B:- 50 GY in 25 fractions over 5weeks. Compare locoregional response in two arms 4 weeks after completion of radiation therapy and at the end of six months of follow up. Compare acute and chronic toxicities in the two arms.

Стилі APA, Harvard, Vancouver, ISO та ін.

Editorial, Article. "RADIOTHERAPY." Diagnostic radiology and radiotherapy 12, no. 1S (April 4, 2021): 133–41. http://dx.doi.org/10.22328/2079-5343-2021-12-s-133-141.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Chaput, Genevieve, and Laura Regnier. "Radiotherapy." Canadian Family Physician 67, no. 10 (October 2021): 753–57. http://dx.doi.org/10.46747/cfp.6710753.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Editorial, Article. "RADIOTHERAPY." Diagnostic radiology and radiotherapy, no. 1S (May 24, 2019): 110–14. http://dx.doi.org/10.22328/2079-5343-2019-s-1-110-114.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Editorial, Artiсle. "RADIOTHERAPY." Diagnostic radiology and radiotherapy, no. 1S (April 22, 2020): 158–65. http://dx.doi.org/10.22328/2079-5343-2020-11-1s-158-165.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Більше джерел

Дисертації з теми "Radiotherapy"

Jain, Pooja. "Optimising Radiotherapy for Cancers affected by Respiratory Motion using Image Guided Radiotherapy." Thesis, University of Manchester, 2008. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.492923.

Повний текст джерела

Анотація:

Conformal and intensity modulated radiotherapy (IMRT) can reduce normal tissue toxicity and facilitate radiation dose escalation by creating steep dose gradients between irradiated volume and normal organs.

Стилі APA, Harvard, Vancouver, ISO та ін.

PINZI, VALENTINA. "Immuno-Radiotherapy for brain glioma: sorting out the immunomodulatory effects of radiotherapy." Doctoral thesis, Università degli Studi di Milano-Bicocca, 2023. https://hdl.handle.net/10281/402376.

Повний текст джерела

Анотація:

BACKGROUND. Glioblastoma (GBM) is a fast-growing and aggressive brain tumor. GBM is the most frequent malignant primary brain tumour and it can result in death in three-six months, if untreated. The current standard of care (SOC) therapy consists in maximal safe surgical resection followed by radiation therapy and adjuvant temozolomide (Stupp protocol), with a median overall survival (OS) of 8-10 months. However, more than half of GBM patients die within one year from the diagnosis, and only 5% survive more than 5 years despite aggressive therapies. Research has now shifted additional attention to methods of modulating the innate immune system for the treatment of GBM. Moreover, radiotherapy, that plays a key role in GBM treatment, has the potential to convert immunologically ‘cold’ tumors into ‘hot’ tumors by a combination of distinct mechanisms. Overall, literature data indicate that local radiation produces systemic, immune-mediated anti¬tumour and, potentially, antimetastatic effects. Additionally, the combination of local radiotherapy and immune-modulation can augment local tumour control and cause distant (abscopal) antitumour effects through increased tumour-antigen release and antigen-presenting cell (APC) cross-presentation, improved dendritic-cell (DC) function, and enhanced T cell priming. In order to sort out the immunomodulatory effects of radiotherapy for brain glioma we conducted this project, also in association with immunetherapy. The radiological response has been evaluated as well. METHODS. Radiotherapy treatment in combination with dendritic cell immunotherapy was evaluated. GL261-glioma bearing immune-competent mice were treated by means of RT (3 fractions, 1 fr/day) as exclusive and concomitant immunotherapy (dendritic cells). Two clinical trials were studied as well. The population was GBM patients treated by means of standard therapy plus DC-vaccine therapy. Response assessment of GBM after radio-chemotherapy and during immunotherapy by delayed contrast trams (treatment response assessment maps) was evaluated as well. RESULTS. Survival, CD8+ T, NK cells were significantly and slightly significant different: control vs RT vs RT-IT. We found that activated microglia persists in both tumor and contralateral brain of irradiated mice. Moreover, RT promoted antitumoral M1 polarization and RT contributed to a massive recruitment of Th1 CD4+ T cells; RT and DC combination contributes to a robust infiltrate of CD8+ T cells. CONCLUSION. Our results confirm that RT can modulate the TME creating a specific chemokine gradient involved in T cell homing. RT in combination with IT can induce an anti-tumour systemic long-lasting effector CD8+ T cell response as well as a local infiltration of NK cells and CD8+ T cells. The combinatorial approach seems to be a promising therapy for GBM patients. It might be evaluated trough other clinical trials in order to confirm the preliminary results.
BACKGROUND. Glioblastoma (GBM) is a fast-growing and aggressive brain tumor. GBM is the most frequent malignant primary brain tumour and it can result in death in three-six months, if untreated. The current standard of care (SOC) therapy consists in maximal safe surgical resection followed by radiation therapy and adjuvant temozolomide (Stupp protocol), with a median overall survival (OS) of 8-10 months. However, more than half of GBM patients die within one year from the diagnosis, and only 5% survive more than 5 years despite aggressive therapies. Research has now shifted additional attention to methods of modulating the innate immune system for the treatment of GBM. Moreover, radiotherapy, that plays a key role in GBM treatment, has the potential to convert immunologically ‘cold’ tumors into ‘hot’ tumors by a combination of distinct mechanisms. Overall, literature data indicate that local radiation produces systemic, immune-mediated anti¬tumour and, potentially, antimetastatic effects. Additionally, the combination of local radiotherapy and immune-modulation can augment local tumour control and cause distant (abscopal) antitumour effects through increased tumour-antigen release and antigen-presenting cell (APC) cross-presentation, improved dendritic-cell (DC) function, and enhanced T cell priming. In order to sort out the immunomodulatory effects of radiotherapy for brain glioma we conducted this project, also in association with immunetherapy. The radiological response has been evaluated as well. METHODS. Radiotherapy treatment in combination with dendritic cell immunotherapy was evaluated. GL261-glioma bearing immune-competent mice were treated by means of RT (3 fractions, 1 fr/day) as exclusive and concomitant immunotherapy (dendritic cells). Two clinical trials were studied as well. The population was GBM patients treated by means of standard therapy plus DC-vaccine therapy. Response assessment of GBM after radio-chemotherapy and during immunotherapy by delayed contrast trams (treatment response assessment maps) was evaluated as well. RESULTS. Survival, CD8+ T, NK cells were significantly and slightly significant different: control vs RT vs RT-IT. We found that activated microglia persists in both tumor and contralateral brain of irradiated mice. Moreover, RT promoted antitumoral M1 polarization and RT contributed to a massive recruitment of Th1 CD4+ T cells; RT and DC combination contributes to a robust infiltrate of CD8+ T cells. CONCLUSION. Our results confirm that RT can modulate the TME creating a specific chemokine gradient involved in T cell homing. RT in combination with IT can induce an anti-tumour systemic long-lasting effector CD8+ T cell response as well as a local infiltration of NK cells and CD8+ T cells. The combinatorial approach seems to be a promising therapy for GBM patients. It might be evaluated trough other clinical trials in order to confirm the preliminary results.

Стилі APA, Harvard, Vancouver, ISO та ін.

Mairs, Robert J. "Targeted radiotherapy of cancer." Thesis, University of Glasgow, 2001. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.248190.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Millin, Anthony. "Verification of stereotactic radiotherapy." Thesis, Cardiff University, 2011. http://orca.cf.ac.uk/12287/.

Повний текст джерела

Анотація:

Investigations have been made into the use of a computer based simulation technique (Monte Carlo (MC)) to ionising radiation transport in order to verify the doses delivered during linear accelerator based stereotactic radiotherapy and radiosurgery. Due to the complex nature of the micro multi-leaf collimators (μMLC) used in this these treatments, a bespoke model of the μMLC was developed and combined with standard component modules to represent the remainder of the linear accelerator. Following validation of the above models, investigations were made into the dosimetry of small fields, defined by the μMLC and measured with a variety of detectors. Comparisons of relative output, profiles and depth doses were made against MC simulations, and a series of correction factors determined, to account for detector geometry and the non water equivalence of materials used in semiconductor detectors. An assessment was then made to determine the smallest fields that can be measured with each detector with confidence. Systems were then developed to independently simulate stereotactic treatments and compare doses simulated with those calculated by the treatment planning system (TPS); excellent agreement between TPS calculations and MC simulations was observed. The application of MC methods to determine the most appropriate treatment tactics and calculation algorithms for stereotactic body radiotherapy in the lung was then investigated with recommendations made on the most appropriate calculation algorithms and beam arrangements for the technique. The doses calculated using the type-b or collapsed cone algorithm agreed most closely with the MC simulation. There was little difference observed between plans using more than four beams in the treatment delivery. Treatment techniques using only three beams or less achieved poorer coverage of the tumour with dose, producing lower doses at the periphery of the tumour near the interface with the surrounding lung tissue, compared to using a greater number of beams. Finally, methods of transit dosimetry using Electronic Portal Imaging Devices were investigated for use in cranial stereotactic radiotherapy. Three methods were investigated based on a full MC simulation of the radiation transport through the patient and on to the imager, prediction of the dose based on a TPS calculation and an approximation of the radiological path length of the central axis of the beams to derive an expected dose at the imager plane. The MC method produced the best agreement at the expense of a longer time to acquire the comparison doses compared to the TPS calculation method. The equivalent path length method showed good agreement (within 3.5%) between delivered and predicted doses but at a single point.

Стилі APA, Harvard, Vancouver, ISO та ін.

Edwards, Craig Richard. "In-vivo radiotherapy dosimetry." Thesis, Keele University, 2002. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.269237.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Helo, Y. "Cerenkov emission in radiotherapy." Thesis, University College London (University of London), 2015. http://discovery.ucl.ac.uk/1469478/.

Повний текст джерела

Анотація:

A new potential quality assurance (QA) method is explored for clinical electron beams and clinical proton beams based on imaging and measuring Cerenkov light. A simulation was performed of the deposited energy and of Cerenkov production in water using Geant4. Monte Carlo simulation was used to predict the measured light distribution around the water phantom, to reproduce Cerenkov images and to find the relation between deposited energy and Cerenkov production. The camera was modelled as a pinhole camera in Geant4, to attempt to reproduce Cerenkov images. The potential of using a standard commercial camera to image Cerenkov light generated from electrons in water for fast QA measurement of a clinical electron beam was explored and compared to ionization chamber measurements. The new method was found to be linear with dose and independent of dose rate (to within 3%). The uncorrected practical range measured using Cerenkov images was found to overestimate the actual value by 3 mm in the worst case. The field size measurements underestimated the field sizes at the edges by 5% without applying any correction factor. Still, the measured field size could be used to monitor relative changes in the beam profile. Finally, the beam-direction profile measurements were independent of the field size within 2%. We found that imaging Cerenkov emission from a breast phantom during electron irradiation could be a suitable tool to monitor the dose and the dose rate consistency with high precision and short-term repeatability better than 3% except when measuring very low doses. Cerenkov light measurements were linear with dose and independent of dose rate. The maximum light intensity occurred at an angle of 45.0°. We were unable to identify the regions of the phantom with higher scattering and absorption properties, designed to mimic diseased tissues using images of Cerenkov emission of an optical breast phantom. We found that the Cerenkov light emissions in proton therapy can be divided into two distinct mechanisms: a fast component due to prompt gamma interactions (99.13%) and neutron interactions (0.87%), and a slow component due to radioactive decay. The simulated depth distribution of the Cerenkov emission shows a strong relation with the depth distribution of the induced radioactive isotopes, which emit positrons. The fast component was found to be linear with dose and independent of dose rate, while the slow component increases non- linearly with dose and is highly dependent on dose rate. Imaging Cerenkov light during electron radiotherapy or proton therapy could be used as a very quick routine QA tool.

Стилі APA, Harvard, Vancouver, ISO та ін.

Allahverdi, Mahmoud. "Accuracy in radiotherapy dosimetry." Thesis, University of Edinburgh, 1998. http://hdl.handle.net/1842/21135.

Повний текст джерела

Анотація:

The project involves an experimental analysis of achievable accuracy in the different steps of radiotherapy, including investigations of the basic dosimetry chain, considering the individual steps concerned in dosimeter and treatment beam calibration and some aspects of treatment planning and dose delivery. The results are investigated from these various areas and are analysed in terms of overall achievable accuracy and its relationship to clinical requirements and to quality assurance programmes. It is concluded that required clinical accuracy can be achieved in radiotherapy treatment, but needs careful control at all stages of the radiotherapy process. In addition a previously-designed geometric phantom, developed for a UK national dosimetry intercomparison and audit system has been used to extensively test achievable accuracy of dosimetry and some basic treatment planning parameters and processes in one department. This has been used as the basis to develop an interdepartmental audit in Scottish and other radiotherapy centres (the so-called Scottish+ audit group, within the UK radiotherapy dosimetry audit network). Also a semianatomic phantom has been developed to allow reasonably realistic audit of various representative treatment sites. This has been constructed from epoxy-based tissue substitute phantom materials. It has been extensively tested before audit use, by measuring the whole range of possible irradiation situations on five megavoltage photon beams, calculating dose distributions using the Edinburgh in-house treatment planning system and CADPLAN, and comparing measured results to expected values. Some small differences can be linked to the phantom materials. Others can be linked to small discrepancies in the testing department, for example in planning data, machine performance, etc.

Стилі APA, Harvard, Vancouver, ISO та ін.

Cecconi, Agnese <1979&gt. "Stereotactict body radiotherapy (SBRT)." Doctoral thesis, Alma Mater Studiorum - Università di Bologna, 2012. http://amsdottorato.unibo.it/4317/1/Cecconi_Agnese_tesi.pdf.

Повний текст джерела

Анотація:

Purpose: evaluation and comparison of volumetric modulated RapidarcTM radiotherapy (RA-IMRT) vs linac based Stereotactic body radiotherapy (SBRT) in the salvage treatment of isolated lymph node recurrences in patients affected by gynaecological cancer. Materials and Methods From January 2010 to September 2011, 15 patients affected by isolated lymph nodes recurrence of gynaecological cancer underwent salvage radiotherapy after conventional imaging staging with CT and 18-FDG-PET/CT. Two different radiotherapy techniques were used in this study: RA-IMRT (RapidarcTM implemented radiotherapy Varian Medical System, Palo Alto, CA, USA) or SBRT (BrainLAB, Feldkirchen, Germany). Five patients underwent CT scan and all patients underwent 18FDG-PET/CT for pre-treatment evaluation and staging. The mean total dose delivered was 54.3 Gy (range 50-60 Gy with conventional fractionation and 27.4 Gy (range 12-40 Gy hypofractionation) for RA-IMRT and SBRT respectively. The mean number of fractions was 27.6 fractions (range 25-31) and 3-4 fractions , the mean overall treatment duration was 40.5 days (range 36-45) and 6.5 days (range 5-8 days) for RA-IMRT and SBRT respectively. Results: At the time of the analysis, October 2011, the overall survival was 92.3 % (80% for RA-IMRT and 100% for SBRT). Six patients are alive with no evidence of disease and also six patients are alive with clinically evident disease in other sites (40% and 50% patients RA-IMRT vs SBRT respectively, one patient died for systemic progression of disease and two patient were not evaluable at this time. Conclusions: Our preliminary results showed that, the use of RA-IMRT and SBRT are an excellent local therapy for isolated lymph nodes recurrences of gynaecological cancer with a good toxicity profile and local control rate, even if any long term survivors would be expected. New treatment modalities like Cyberknife are also being implemented.

Стилі APA, Harvard, Vancouver, ISO та ін.

Cecconi, Agnese <1979&gt. "Stereotactict body radiotherapy (SBRT)." Doctoral thesis, Alma Mater Studiorum - Università di Bologna, 2012. http://amsdottorato.unibo.it/4317/.

Повний текст джерела

Анотація:

Стилі APA, Harvard, Vancouver, ISO та ін.

Taylor, Alexandra. "Intensity-modulated radiotherapy for cervical cancer : optimising target volume definition and radiotherapy delivery." Thesis, University of London, 2008. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.510901.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Більше джерел

Книги з теми "Radiotherapy"

Foundation, Lisa Sainsbury, ed. Radiotherapy. London: Austen Cornish in association with the Lisa Sainsbury Foundation, 1988.

Знайти повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Rath, Arabinda Kumar, and Narayan Sahoo, eds. Particle Radiotherapy. New Delhi: Springer India, 2016. http://dx.doi.org/10.1007/978-81-322-2622-2.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Calvo, Felipe Angel, Luther W. Brady, and Manual Santos, eds. Intraoperative Radiotherapy. Berlin, Heidelberg: Springer Berlin Heidelberg, 1992. http://dx.doi.org/10.1007/978-3-642-84183-5.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

International Cancer Research Data Bank., ed. Intraoperative radiotherapy. Bethesda, MD (Bldg. 82, Rm. 103, Bethesda 20892): U.S. Department of Health and Human Services, Public Health Service, National Institutes of Health, National Cancer Institute, International Cancer Research Data Bank, 1988.

Знайти повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Rich, Tyvin A. Intraoperative radiotherapy. Bethesda, MD (Bldg. 82, Rm. 103, Bethesda 20892): U.S. Department of Health and Human Services, Public Health Service, National Institutes of Health, National Cancer Institute, International Cancer Research Data Bank, 1988.

Знайти повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Bleehen, Norman M. Radiobiology in Radiotherapy. London: Springer London, 1988.

Знайти повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Priestman, Terry J. Coping with radiotherapy. London: Sheldon Press, 2007.

Знайти повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Tsuboi, Koji, Takeji Sakae, and Ariungerel Gerelchuluun, eds. Proton Beam Radiotherapy. Singapore: Springer Singapore, 2020. http://dx.doi.org/10.1007/978-981-13-7454-8.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Tsujii, Hirohiko, Tadashi Kamada, Toshiyuki Shirai, Koji Noda, Hiroshi Tsuji, and Kumiko Karasawa, eds. Carbon-Ion Radiotherapy. Tokyo: Springer Japan, 2014. http://dx.doi.org/10.1007/978-4-431-54457-9.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Gaya, Andrew, and Anand Mahadevan, eds. Stereotactic Body Radiotherapy. London: Springer London, 2015. http://dx.doi.org/10.1007/978-0-85729-597-2.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Більше джерел

Частини книг з теми "Radiotherapy"

Marcus, Karen J. "Radiotherapy." In Pediatric Head and Neck Tumors, 31–37. New York, NY: Springer New York, 2013. http://dx.doi.org/10.1007/978-1-4614-8755-5_4.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Burton, Kate E. "Radiotherapy." In Management of Adult Glioma in Nursing Practice, 213–27. Cham: Springer International Publishing, 2019. http://dx.doi.org/10.1007/978-3-319-76747-5_14.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Dhillon, Ramindar S., and James W. Fairley. "Radiotherapy." In Multiple-choice Questions in Otolaryngology, 210. London: Palgrave Macmillan UK, 1989. http://dx.doi.org/10.1007/978-1-349-10805-3_307.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Zafonte, Ross, and Brad Kurowski. "Radiotherapy." In Encyclopedia of Clinical Neuropsychology, 2931–32. Cham: Springer International Publishing, 2018. http://dx.doi.org/10.1007/978-3-319-57111-9_66.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Veronesi, Umberto. "Radiotherapy." In Breast Cancer, 46–49. Berlin, Heidelberg: Springer Berlin Heidelberg, 1990. http://dx.doi.org/10.1007/978-3-642-76054-9_7.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Takayama, Kanako, Yusuke Demizu, and Nobukazu Fuwa. "Radiotherapy." In Oral Cancer, 285–306. Tokyo: Springer Japan, 2015. http://dx.doi.org/10.1007/978-4-431-54938-3_11.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Zafonte, Ross, and Brad Kurowski. "Radiotherapy." In Encyclopedia of Clinical Neuropsychology, 1–2. Cham: Springer International Publishing, 2017. http://dx.doi.org/10.1007/978-3-319-56782-2_66-2.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Hoogewoud, Henri-Marcel. "Radiotherapy." In Hepatocellular Carcinoma and Liver Metastases: Diagnosis and Treatment, 62–69. Berlin, Heidelberg: Springer Berlin Heidelberg, 1993. http://dx.doi.org/10.1007/978-3-642-77981-7_5.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Loch, Irene, and Jane Khorrami. "Radiotherapy." In Pediatric Oncology, 233–41. Berlin, Heidelberg: Springer Berlin Heidelberg, 2010. http://dx.doi.org/10.1007/978-3-540-87984-8_10.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Greco, Carlo, and Bruce D. Minsky. "Radiotherapy." In Liver Metastases, 153–60. London: Springer London, 1998. http://dx.doi.org/10.1007/978-1-4471-1506-9_12.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Тези доповідей конференцій з теми "Radiotherapy"

Bustillo, J. P. O., J. R. Posadas, E. Inocencio, V. de Rover, M. Cameron, E. Engels, A. Rosenfeld, and M. Lerch. "Fabricated heterogeneous head radiotherapy phantoms for Synchrotron and Linac X-ray radiotherapy: characterization and dosimetry." In 2024 IEEE Nuclear Science Symposium (NSS), Medical Imaging Conference (MIC) and Room Temperature Semiconductor Detector Conference (RTSD), 1–2. IEEE, 2024. http://dx.doi.org/10.1109/nss/mic/rtsd57108.2024.10655300.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Kanai, Tatsuaki. "Heavy-ion radiotherapy." In Second international conference on atomic and molecular data and their applications. AIP, 2000. http://dx.doi.org/10.1063/1.1336267.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Bedford, Linda. "17 Palliative radiotherapy." In Marie Curie Palliative Care Research Conference. British Medical Journal Publishing Group, 2019. http://dx.doi.org/10.1136/spcare-2019-mariecuriepalliativecare.17.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Mullaney, Tara. "Emotional wellbeing and radiotherapy." In Procedings of the Second Conference. New York, New York, USA: ACM Press, 2011. http://dx.doi.org/10.1145/2079216.2079280.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Guo, Wei, Ralf Muller-Polyzou, Zhen Chen, Nicolas Meier, and Anthimos Georgiadis. "Patient Positioning in Radiotherapy." In 2020 IEEE International Symposium on Medical Measurements and Applications (MeMeA). IEEE, 2020. http://dx.doi.org/10.1109/memea49120.2020.9137355.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

"Radiotherapy and Medical Instrumentations." In Proceedings of the 11th Conference. WORLD SCIENTIFIC, 2010. http://dx.doi.org/10.1142/9789814307529_others06.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

"Proffered papers: Radiotherapy technical." In Proceedings of UK Imaging and Oncology Congress Online 2023. The British Institute of Radiology, 2023. http://dx.doi.org/10.1259/conf-pukrc.2023-c-radiotech.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

West, Catharine M. L. "Abstract IA-021: Predicting radiotherapy outcomes: Radiogenomics and risk of radiotherapy toxicity." In Abstracts: AACR Virtual Special Conference on Radiation Science and Medicine; March 2-3, 2021. American Association for Cancer Research, 2021. http://dx.doi.org/10.1158/1557-3265.radsci21-ia-021.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Leonard, CE, RD Sobus, S. Fryman, S. Sedlacek, J. Kercher, J. Widner, L. Asmar, et al. "Abstract P1-10-03: A randomized trial of accelerated breast radiotherapy utilizing either 3-dimensional radiotherapy versus intensity modulated radiotherapy." In Abstracts: 2016 San Antonio Breast Cancer Symposium; December 6-10, 2016; San Antonio, Texas. American Association for Cancer Research, 2017. http://dx.doi.org/10.1158/1538-7445.sabcs16-p1-10-03.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Milosavljević, Neda, Marija Živković Radojević, Darko Stojanović, Katarina Janković, and Tatjana B. Miladinović. "A protocol for thoracic radiation therapy in patients with cardiac implantable electronic devices." In 2nd International Conference on Chemo and Bioinformatics. Institute for Information Technologies, University of Kragujevac, 2023. http://dx.doi.org/10.46793/iccbi23.193m.

Повний текст джерела

Анотація:

Prolonged lifespan and improved diagnostic and treatment modalities have led to significant progress in the diagnosis and treatment of cardiovascular disease and cancer. A substantial number of patients with malignancies also have cardiovascular disease at the time of cancer treatment. Per literature, over one million implantable cardiac devices are inserted annually. Ionizing radiation, especially in the thoracic area is related to cardiac implantable electronic device (CIED) damage and malfunction. Besides that, CIED can interfere with radiotherapy planning and delivery, as well as patient motivation to undergo radiotherapy treatment. Management of oncology patients, undergoing radiotherapy, for any indication, with a CIED is essential, and safe radiotherapy practice requires minimizing the risk to patients as much as possible, from pretherapy planning to posttherapy follow-up. A collaborative multidisciplinary approach, tailor-made for every single radiotherapy center is imperative to provide effective and safe radiotherapy for these patients. A collaboration of radiation oncologists, medical physicists and cardiologists from the University Clinical Center Kragujevac has created a local protocol for radiotherapy treatment and follow-up for patients receiving radiotherapy at the Center for Radiation Oncology University C linical Center Kragujevac, which provides safe and efficient delivery of an adequate radiotherapy dose to target volumes with appropriate cardiac monitoring.

Стилі APA, Harvard, Vancouver, ISO та ін.

Звіти організацій з теми "Radiotherapy"

Alonso-Basanta, Michelle, Carol Armstrong, Manoj Kumar, Harish Poptani, Zelig Tochner, Ron Wolf, Tim Zhu, Lilie Lin, Alexander Lin, and Robert Lustig. Neurocognitive Effects of Radiotherapy. Fort Belvoir, VA: Defense Technical Information Center, October 2014. http://dx.doi.org/10.21236/ada612059.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Reinstein, Lawrence E., Howard I. Amols, Peter J. Biggs, Ronald T. Droege, Alexander B. Filimonov, Wendell R. Lutz, and Shlomo Shalev. Radiotherapy Portal Imaging Quality. AAPM, 1987. http://dx.doi.org/10.37206/23.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Tochner, Zelig, Carol Armstrong, Manoj Kumar, Harish Poptani, Michelle Alonso-Basanta, Robert Lustig, Peter Gabriel, and Christine Hill-Kayser. Neurocognitive Effects of Radiotherapy. Fort Belvoir, VA: Defense Technical Information Center, October 2015. http://dx.doi.org/10.21236/ada624109.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Xiao, Youchao, Wentao Wu, Lu Jin, Yanfei Jia, Kefan Cai, Ning Qiao, Lei Cao, and Songbai Gui. Association between radiotherapy and follow-up obesity in craniopharyngioma: a mini-review and meta-analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, December 2022. http://dx.doi.org/10.37766/inplasy2022.12.0008.

Повний текст джерела

Анотація:

Review question / Objective: The effect of radiotherapy on post-treatment weight is incompletely defined. We determined the associations between radiotherapy and follow-up obesity in patients with craniopharyngioma (CP). Eligibility criteria: The inclusion criteria were as follows: (1) Participants: Patients who were clinically diagnosed with craniopharyngioma; (2) Intervention/control: For the control group, patients have not received radiotherapy, and the patients of the intervention group received radiotherapy alone, or surgery combined radiotherapy, or radiotherapy combined adjuvant therapy; (3) Outcome: The outcome was postoperative BMI or postoperative obesity. We excluded studies with (1) in vitro or animal experiments; (2) not written in English; (3) conference abstracts, reviews, correspondence, and comments; (4) case reports that included less than 10 patients.

Стилі APA, Harvard, Vancouver, ISO та ін.

Buchsbaum, Donald J. Genetic Radiotherapy of Prostate Cancer. Fort Belvoir, VA: Defense Technical Information Center, December 2003. http://dx.doi.org/10.21236/ada422767.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Raghavan Rajagopalan. Targeted Radiotherapy of Estrogen Receptor Positive Tumors. Office of Scientific and Technical Information (OSTI), August 2006. http://dx.doi.org/10.2172/896748.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Winter, Hayden. Synthesis and Assessment of Radiotherapy-Enhancing Nanoparticles. Portland State University Library, January 2000. http://dx.doi.org/10.15760/etd.7421.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Li, Chuan-Yuan. Enhancement of Prostate Cancer Radiotherapy by Immunogenetherapy. Fort Belvoir, VA: Defense Technical Information Center, February 2004. http://dx.doi.org/10.21236/ada424647.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Stovall, Marilyn, Charles Robert Blackwell, Jackson Cundiff, Devorah H. Novack, Jatinder R. Palta, Louis K. Wagner, Edward W. Webster, and Robert J. Shalek. Fetal Dose from Radiotherapy with Photon Beams. AAPM, 1995. http://dx.doi.org/10.37206/49.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Charatsi, Dimitra, Polyxeni Vanakara, Michail Nikolaou, Aikaterini Evaggelopoulou, Dimitrios Korfias, Foteini Simopoulou, Nikolaos Charalampakis, et al. Vaginal Dilator Use to Promote Sexual Wellbeing After Radiotherapy in Gynaecological Cancer Survivors: A Prospective Observational Study. Science Repository, October 2021. http://dx.doi.org/10.31487/j.ijcst.2021.03.01.sup.

Повний текст джерела

Анотація:

Background: Since continuing advances in radiotherapy technology broaden the role of radiotherapy in the treatment of gynaecologic malignancies, the use of vaginal dilators has been introduced in order to mitigate the risk of vaginal stenosis. The main aims of this study were to investigate the vaginal dilator use efficacy in the treatment of radiation-induced vaginal stenosis and the vaginal dilator effect on sexual quality of life. Methods: We studied fifty-three patients with endometrial or cervical cancer. The participants were treated with radical or adjuvant external beam radiotherapy and/or brachytherapy. They were routinely examined at four time points post-radiotherapy when also they were asked to fill in a validated sexual function-vaginal changes questionnaire. A p-value less than 0.05 was considered statistically significant. Results: The vaginal stenosis grading score was decreased and the size of the vaginal dilator comfortably insertable was gradually increased throughout the year of vaginal dilator use while radiation-induced vaginal and sexual symptoms were improved throughout the year of VD use. All patients with initial grade 3 showed vaginal stenosis of grade 2 after 12 months of vaginal dilator use and 65.8% of the patients with grade 2 initial vaginal stenosis demonstrated final vaginal stenosis grade 1 while 77.8% of the participants with initial 1st size of vaginal dilators reached the 3rd vaginal dilator size after 12 months. Starting time of dilator therapy <= 3 months after the end of radiotherapy was associated with a significant decrease in vaginal stenosis. Additionally, there was an overall upward trend regarding patients’ satisfaction with their sexual life. Conclusion: Endometrial and cervical cancer survivors should be encouraged to use vaginal dilators for the treatment of vaginal stenosis and sexual rehabilitation after radiotherapy.

Стилі APA, Harvard, Vancouver, ISO та ін.

Ми пропонуємо знижки на всі преміум-плани для авторів, чиї праці увійшли до тематичних добірок літератури. Зв'яжіться з нами, щоб отримати унікальний промокод!